[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stoke Therapeutics, Inc.$26.6141 per share and 20,682 shares at a weighted average price of $27.3361 per share, in each case coded as an open market sale. After these transactions, the director beneficially owned 364,246 shares of Stoke Therapeutics common stock in direct form.

The filing states that the trades were executed under a Rule 10b5-1 trading plan adopted on August 15, 2025, which is designed to provide an affirmative defense for pre-arranged trading. The prices reported reflect multiple individual trades within stated price ranges, and the reporting person has agreed to provide detailed breakdowns of the prices upon request.

11/18/2025 - 04:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krainer Adrian R.

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		S(1)		19,790	D	$26.6141(2)	384,928	D
Common Stock	11/14/2025		S(1)		20,682	D	$27.3361(3)	364,246	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.975 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.88 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report on this Form 4?

The Form 4 reports that a director of Stoke Therapeutics, Inc. sold shares of common stock in two open market transactions on 11/14/2025.

How many Stoke Therapeutics (STOK) shares were sold in the reported transactions?

The director sold 19,790 shares of common stock at one weighted average price and 20,682 shares at another weighted average price on 11/14/2025.

What prices were received for the Stoke Therapeutics (STOK) shares sold?

The reported weighted average prices were $26.6141 per share for 19,790 shares (with individual trades from $25.975 to $26.97) and $27.3361 per share for 20,682 shares (with trades from $26.98 to $27.88).

How many Stoke Therapeutics (STOK) shares does the director own after these sales?

Following the reported transactions, the director beneficially owned 364,246 shares of Stoke Therapeutics common stock in direct form.

Was the Stoke Therapeutics (STOK) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were executed under a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

What is the relationship of the reporting person to Stoke Therapeutics (STOK)?

The reporting person is identified as a director of Stoke Therapeutics, Inc., and the Form 4 is filed for one reporting person.

Are detailed trade prices for the Stoke Therapeutics (STOK) insider sale available?

The filing notes that the reporting person will provide full information on the number of shares sold at each separate price within the disclosed ranges upon request to the issuer, any security holder, or the SEC staff.